Ethyl 2-(3-Cyanophenyl)-4-methyl-1-(pyridin-4-ylmethoxy)-1H-imidazole-5-carboxylate

ID: ALA4756830

PubChem CID: 162655297

Max Phase: Preclinical

Molecular Formula: C20H18N4O3

Molecular Weight: 362.39

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCOC(=O)c1c(C)nc(-c2cccc(C#N)c2)n1OCc1ccncc1

Standard InChI:  InChI=1S/C20H18N4O3/c1-3-26-20(25)18-14(2)23-19(17-6-4-5-16(11-17)12-21)24(18)27-13-15-7-9-22-10-8-15/h4-11H,3,13H2,1-2H3

Standard InChI Key:  BSWPZPGRYUWNPP-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   40.7013  -19.1420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.7002  -19.9616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.4082  -20.3705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.1179  -19.9611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.1150  -19.1384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.4064  -18.7332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.8190  -18.7289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.5668  -19.0584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   44.1113  -18.4490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7000  -17.7428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.9014  -17.9159    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   44.9243  -18.5314    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.0295  -16.9950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.8419  -16.9065    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   43.5466  -16.3357    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   45.1714  -16.1586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.9838  -16.0701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.4110  -21.1837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.4108  -22.0009    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   42.2920  -17.3714    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   41.5158  -17.6269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.9064  -17.0824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.0767  -16.2861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.4681  -15.7418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.6910  -15.9972    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   39.5258  -16.8018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.1357  -17.3426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11  7  1  0
  5  7  1  0
  9 12  1  0
 10 13  1  0
 13 14  1  0
 13 15  2  0
 14 16  1  0
 16 17  1  0
 18 19  3  0
  3 18  1  0
 11 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 22  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4756830

    ---

Associated Targets(non-human)

Plasma (649 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 362.39Molecular Weight (Monoisotopic): 362.1379AlogP: 2.93#Rotatable Bonds: 6
Polar Surface Area: 90.03Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 4.99CX LogP: 2.36CX LogD: 2.36
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.63Np Likeness Score: -1.47

References

1. Lei Y,Zhang B,Liu D,Zhao J,Dai X,Gao J,Mao Q,Feng Y,Zhao J,Lin F,Duan Y,Zhang Y,Bao Z,Yang Y,Mou Y,Wang S.  (2020)  Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.,  63  (24): [PMID:33307675] [10.1021/acs.jmedchem.0c01524]

Source